sweroside has been researched along with Non-alcoholic Fatty Liver Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Ding, Y; Hu, K; Huang, M; Li, Y; Yang, Q | 1 |
| Cheng, R; Ding, L; Ding, P; Gong, J; Huang, W; Li, J; Shu, F; Sun, H; Tong, R; Wang, Z; Yang, L; Yang, Q | 1 |
| Cho, YY; Han, SH; Jang, JH; Jang, JK; Kang, HC; Kim, SW; Lee, HS; Lee, JY; Ma, KH; Yang, G | 1 |
3 other study(ies) available for sweroside and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Sweroside alleviates hepatic steatosis in part by activating AMPK/mTOR-mediated autophagy in mice.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Diet, High-Fat; Lipid Metabolism; Liver; Mammals; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; TOR Serine-Threonine Kinases | 2023 |
Sweroside ameliorates NAFLD in high-fat diet induced obese mice through the regulation of lipid metabolism and inflammatory response.
Topics: Animals; CD36 Antigens; Diet, High-Fat; Disease Models, Animal; Fibroblast Growth Factors; Gene Regulatory Networks; HEK293 Cells; Humans; Inflammation Mediators; Insulin Resistance; Iridoid Glucosides; Lipid Metabolism; Liver; Male; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Obesity; PPAR alpha; Transcriptome; Weight Gain | 2020 |
Sweroside Prevents Non-Alcoholic Steatohepatitis by Suppressing Activation of the NLRP3 Inflammasome.
Topics: Animals; Caspase 1; Choline; Diet; Disease Models, Animal; DNA, Mitochondrial; Gene Expression Regulation; Injections, Intraperitoneal; Interleukin-1beta; Iridoid Glucosides; Liver; Macrophages; Methionine; Mice; Mitochondria, Liver; NLR Family, Pyrin Domain-Containing 3 Protein; Non-alcoholic Fatty Liver Disease; Treatment Outcome | 2020 |